- Walne zgromadzenie
- Ład i dokumenty korporacyjne
- Akcje i akcjonariat
- Pierwsza oferta publiczna
- 22.12.2020Captor Therapeutics and Sosei Heptares Enter Strategic Collaboration
Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
- 22.10.2020Captor Therapeutics as one of the „Scrip’s 10 To Watch”
We have been selected as one of the „Scrip’s 10 To Watch” companies at #BIOEurope Digital 2020!
- 24.04.2020A new project in the area of autoimmune diseases
We have received over 27 M PLN grant for a new project!
- 05.03.2020Advancing the technological platform
A new grant will support...
- 21.02.2020Captor's review article
Our review on protein degradation technology has been published in "Technology Transfer and Entrepreneurship"...
- 30.01.2020Captor's oncological program received funding
Discovery and development of a new clinical drug candidate in the treatment of hepatocellular carcinoma...
- 19.12.2019Our new chemistry lab
We are happy to announce that our brand new chemistry lab is ready!
- 02.12.2019Dr Tom Shepherd joins our team
Tom Shepherd, Ph.D. as Captor Therapeutics' Chief Business Officer (CBO)...